Italian study backs Matritech's bladder cancer test:
This article was originally published in Clinica
Executive Summary
Matritech's NMP22 urine test for bladder cancer is better at detecting the disease than traditional urine cytology or the bladder tumour antigen (BTA) test, according to an Italian study. Researchers at the Institute of Urology in Milan compared the three tests in 105 bladder cancer patients. They found that NMP22 levels showed a sensitivity of 92% for transitional cell carcinoma of the bladder compared with 46.6% for urinary cytology and 50.6% for the BTA test which is made by Polymedco of Cortlandt Manor, New York. The study is published in the February issue of European Urology.